Clinical Trials

Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma


Study ID
Amgen 20170122

NCT Number
NCT03287908 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0624

Principle Investigator
Dr. David Siegel

Phase
I

Sponsor
Amgen


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now